What Is Sermorelin?
Sermorelin is the biologically active N-terminal fragment of the 44-amino acid human GHRH molecule. Research in the early 1980s established that amino acids 1 through 29 of GHRH retain full biological activity at the pituitary GHRH receptor, making sermorelin the shortest fully functional fragment of the native hormone. Its amino acid sequence is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂, with a molecular weight of approximately 3,358 Da.
The FDA approved sermorelin injection (0.05 mg/amp) under NDA 19-863 in December 1990 for diagnostic use, followed by approval of Geref (0.5 mg and 1.0 mg vials) under NDA 20-443 in September 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure. EMD Serono, the sole manufacturer, voluntarily ceased production in 2008 as recombinant human growth hormone (rhGH) dominated the pediatric GHD market, making Geref commercially unviable. The FDA formally withdrew NDA approval in June 2009 but confirmed in a 2013 Federal Register notice that the withdrawal was not for reasons of safety or effectiveness.
What distinguishes sermorelin from other GHRH analogs is its close structural identity to native GHRH. Unlike CJC-1295, which incorporates amino acid substitutions and (in its DAC form) an albumin-binding moiety to extend its half-life to days, sermorelin has a plasma half-life of only 11 to 12 minutes, producing brief, physiological pulses of GH release. Compared to tesamorelin, a 44-amino acid modified GHRH analog currently FDA-approved for HIV-associated lipodystrophy, sermorelin is smaller and less resistant to enzymatic degradation but has a longer clinical track record across a broader range of indications. See the sermorelin vs CJC-1295 comparison for a full breakdown of these two GHRH analogs.
Proposed benefits of sermorelin include:
- Stimulation of endogenous growth hormone production from the pituitary
- Increased IGF-1 levels and downstream anabolic signaling
- Improved body composition (increased lean mass, reduced body fat)
- Enhanced deep sleep (slow-wave sleep) architecture
- Improved skin thickness and collagen synthesis
- Preservation of the hypothalamic-pituitary feedback axis
- Potential improvements in insulin sensitivity and metabolic health
How It Works
GHRH Receptor Activation
Sermorelin binds to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. The GHRHR is a G protein-coupled receptor that, upon activation, triggers the Gs/adenylyl cyclase/cAMP signaling pathway along with mitogen-activated protein kinase (MAPK) cascades. This stimulates both the synthesis and secretion of growth hormone from somatotroph cells.
Critically, sermorelin's GH-releasing effect is modulated by somatostatin, the hypothalamic inhibitory hormone that opposes GHRH signaling. When somatostatin tone is high (during waking hours and after meals), sermorelin's efficacy is reduced. When somatostatin tone naturally falls, particularly during early sleep, sermorelin's stimulatory effect is amplified. This interplay explains why bedtime administration is the standard protocol: it aligns exogenous GHRH stimulation with the body's natural window of maximal GH secretory potential.
Growth Hormone Cascade
Once growth hormone is released into the circulation, it binds to GH receptors in the liver, stimulating production of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of GH's downstream effects: protein synthesis in skeletal muscle, chondrocyte proliferation in cartilage, osteoblast activation in bone, and lipolysis in adipose tissue. Clinical studies of sermorelin in elderly adults have demonstrated significant increases in IGF-1 levels within 2 to 4 weeks of treatment, with IGF-1 remaining elevated throughout the treatment period.
The GH-IGF-1 axis also exerts broad metabolic effects, including improvements in lipid profiles, increased glucose disposal in skeletal muscle, and enhanced nitrogen retention, collectively contributing to the body composition changes observed with sustained sermorelin therapy.
Hypothalamic-Pituitary Axis Preservation
One of sermorelin's most important pharmacological advantages is its preservation of the hypothalamic-pituitary-somatotropic (HPS) axis. Exogenous GH administration delivers a constant, supraphysiological hormone load that suppresses endogenous GH production through negative feedback on both the hypothalamus and pituitary. Over time, this can cause somatotroph atrophy and prolonged suppression of natural GH secretion after discontinuation.
Sermorelin, by contrast, works upstream of the pituitary. It stimulates the same receptor that endogenous GHRH activates, and the resulting GH release remains subject to somatostatin-mediated negative feedback. The pituitary releases GH in its natural pulsatile pattern rather than the flat, sustained elevation produced by exogenous GH injections. Studies have shown that when sermorelin is discontinued, GH levels return to baseline without evidence of prolonged suppression. The pituitary's secretory capacity appears to be maintained or even restored in some cases.
Effects on Sleep Architecture
The relationship between GHRH and slow-wave sleep (SWS) is bidirectional. GHRH signaling promotes SWS onset and duration, while SWS itself creates the hormonal environment (low somatostatin, high GHRH tone) that facilitates the largest GH pulse of the 24-hour cycle. This nocturnal surge represents 60% to 70% of total daily GH secretion in men (the proportion is lower and more variable in women) and can reach concentrations 10 to 20 times higher than daytime levels.
Clinical studies have demonstrated that pulsatile GHRH administration during the first half of the night significantly increases both GH secretion and time spent in slow-wave sleep. Bedtime sermorelin injections leverage this physiology, reinforcing the natural nocturnal GH surge rather than disrupting circadian hormone patterns.